Abstract: In view of the worldwide burden of cardiovascular disease and the high cost of and poor adherence to medication regimens for the prevention of cardiovascular disease, the concept of a "polypill" — a single pill that combines several medications — is an attractive public health approach. However, evidence that each component of a polypill would independently reduce the risk of cardiovascular events and that the combination of agents would be safe is lacking. The primary results of the Heart Outcomes Prevention Evaluation (HOPE)–3 trial are now reported in three articles in the Journal.13 HOPE-3 was a double-blind, randomized, . . .
Publication Year: 2016
Publication Date: 2016-04-02
Language: en
Type: letter
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 21
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot